LFWD and ORMP Related Headlines
Go Back- Lifeward raises $5.6M in convertible notes with $5.6M more tied to milestones
- Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
- Oramed to join Russell indexes amid $270M balance sheet
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- Lifeward closes strategic partnership with Oramed
- Lifeward Successfully Closes on Strategic Partnership with Oramed
- Lifeward receives shareholder approval for Oramed partnership deal
- Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
- Lifeward enters $47 million strategic partnership with Oramed
- Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
- Oramed to transfer drug delivery tech to Lifeward for 49.9% stake
- Oramed and Lifeward Announce Strategic Transaction
LFWD and ORMP Related Press Releases
Go Back- Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- Lifeward Successfully Closes on Strategic Partnership with Oramed
- Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
- Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
- Oramed and Lifeward Announce Strategic Transaction
